Core Viewpoint - Junsheng Tai Pharmaceutical-B (02511) experienced a nearly 8% increase in stock price, reaching HKD 3.4, with a trading volume of HKD 5.8183 million, following the release of its interim results for the six months ending June 30, 2025 [1] Financial Performance - Other income for the company was RMB 10.542 million, representing a year-on-year decrease of 69.96% [1] - The loss attributable to shareholders was RMB 120 million, which narrowed by 42.96% year-on-year [1] - Basic loss per share was RMB 0.27 [1] Product Development - The company's core product, HTD1801, is a globally innovative oral anti-inflammatory and metabolic regulator targeting the gut-liver system [1] - HTD1801 is currently under global development for the treatment of CKM-related diseases, including Type 2 Diabetes Mellitus (T2DM), Metabolic Associated Fatty Liver Disease (MASH), Chronic Kidney Disease (CKD), obesity, Primary Sclerosing Cholangitis (PSC), and Severe Hypertriglyceridemia (SHTG) [1]

Core Viewpoint - Junsheng Tai Pharmaceutical-B (02511) experienced a nearly 8% increase in stock price, reaching HKD 3.4, with a trading volume of HKD 5.8183 million [1] Financial Performance - The company reported a decrease in other income to RMB 10.542 million, a year-on-year decline of 69.96% [1] - Shareholder loss narrowed to RMB 120 million, a year-on-year reduction of 42.96% [1] - Basic loss per share was RMB 0.27 [1] Product Development - The core product HTD1801 is a globally innovative oral anti-inflammatory and metabolic regulator targeting the gut-liver system [1] - HTD1801 is under global development for treating CKM-related diseases, including Type 2 Diabetes Mellitus (T2DM), Metabolic Associated Fatty Liver Disease (MASH), Chronic Kidney Disease (CKD), Obesity, Primary Sclerosing Cholangitis (PSC), and Severe Hypertriglyceridemia (SHTG) [1]

Core Viewpoint - Junsheng Tai Pharmaceutical-B reported a significant reduction in losses for the first half of 2025, with a loss of 113.9 million yuan compared to a loss of 210.9 million yuan in the same period of 2024 [1] Group 1: Financial Performance - The company recorded a loss of 113.9 million yuan in the first half of 2025, which is a substantial improvement from the 210.9 million yuan loss in the first half of 2024 [1] Group 2: Product Development - The core product HTD1801 is a globally innovative oral anti-inflammatory and metabolic regulator targeting the gut-liver system, currently under development for CKM-related diseases [1] - HTD1801 is being developed for multiple conditions, including Type 2 Diabetes Mellitus (T2DM), Metabolic Associated Fatty Liver Disease (MASH), Chronic Kidney Disease (CKD), Obesity, Primary Sclerosing Cholangitis (PSC), and Severe Hypertriglyceridemia (SHTG) [1] - A new indication for HTD1801 has been added for Chronic Kidney Disease, showing potential in regulating various pathogenic mechanisms related to kidney diseases [1] - HTD1801 demonstrates significant therapeutic potential in the CKD field, with advantages in improving eGFR (estimated Glomerular Filtration Rate) trends compared to competing drugs [1] - The company is preparing for a Phase II clinical study of HTD1801 for the treatment of CKD [1] Group 3: Pipeline Candidates - In addition to HTD1801, the company has developed a strong pipeline of innovative candidate drugs, including HTD4010, HTF1037, HTF1057, HTD1804, HTD1805, and HTD2802, targeting ten potential indications [1]

格隆汇8月25日丨君圣泰医药-B(02511.HK)公布中期业绩，2025年上半年，集团录得亏损人民币1.139亿 元，较2024年同期亏损人民币2.109亿元大幅收窄。集团的创新产品管线能够使集团在全球快速增长的 重大代谢疾病治疗市场中抓住机遇。应对代谢疾病及炎症相关共病的核心策略是挖掘HTD1801的潜 力，拓展其适应症范围，目前，HTD1801正在全球范围内开发，用于治疗CKM相关疾病，包括二型糖 尿病(T2DM)、代谢相关脂肪性肝炎(MASH)、慢性肾病(CKD)、肥胖症、原发性硬化性胆管炎(PSC)及 严重高甘油三酯血症(SHTG)。除HTD1801外，集团亦研发出具备同样创新性的强大候选药物管线，包 括HTD4010、HTF1037、HTF1057、HTD1804、HTD1805及HTD2802，集团的产品管线共针对十种潜在 适应症。 HTD1801是唯一通过激活AMPK和抑制NLRP3炎症小体双机制，以解决心肾代谢系统疾病(CKM)的临床 阶段化合物。CKM是一类由心脏疾病、肾脏疾病及代谢紊乱(如糖尿病、肥胖症等)共同构成的复杂健康 障碍。尽管现有标准疗法已取得显着进展，但在CKM相关疾病中仍存 ...

Core Viewpoint - Junsheng Tai Pharmaceutical-B (02511) reported a significant decline in other income and a narrowed loss for the six months ending June 30, 2025, indicating challenges in revenue generation but improved loss management [1] Financial Performance - Other income amounted to 10.542 million yuan, representing a year-on-year decrease of 69.96% [1] - Shareholders' loss was 120 million yuan, which is a year-on-year reduction of 42.96% [1] - Basic loss per share was 0.27 yuan [1] Revenue Drivers - The decrease in other income was primarily attributed to a reduction in government subsidies by approximately 19.1 million yuan [1]

公告称，其他收入减少乃主要由于政府补助减少约1910万元。 智通财经APP讯，君圣泰医药-B(02511)发布截至2025年6月30日止六个月的中期业绩，其他收入1054.2 万元(人民币，下同)，同比减少69.96%;股东应占亏损1.2亿元，同比收窄42.96%;每股基本亏损0.27元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 HighTide Therapeutics, Inc. （於開曼群島註冊成立的有限公司） （股份代號：2511） 截至二零二五年六月三十日止六個月的中期業績公告 君圣泰医藥（「本公司」，連同其子公司統稱「本集團」）董事（「董事」）會（「董事 會」）欣然公佈本集團截至二零二五年六月三十日止六個月（「報告期間」）的未經審 核綜合中期業績連同截至二零二四年六月三十日止六個月的比較數字。 於本公告內，「我們」及「我們的」均指本公司，如文義另有所指，則指本集團。 本公告所載若干金額及百分比數字已約整或已四捨五入至小數點後一位或兩位數 （如適用）。任何表格、圖表或其他地方所示總額與本公告所列數額總和如有任何 差異乃因四捨五入所致。 管理層討論及分析 概覽 我們是一家新型生物醫藥公司，專注於研究和開發代謝性疾病領域的突破性治療 方案，為全球患者帶來綜合獲益。 代謝性慢病治療領域存在重大的未滿足臨床需求，給患者和其家庭 ...

君圣泰医药-B(2511.HK)今日盘中一度大涨10%至3.39港元，年内累涨1.67倍。 君圣泰医药昨日晚间公告，集团的全资附属公司深圳君圣泰生物技术有限公司与中国医学科学院医药生物技术研究所("药生所")共同开展课题合作，评估集 团核心产品HTD1801对糖尿病伴慢性肾病(CKDwithT2DM)的治疗潜力。双方围绕异喹啉类新药共同开展药效与机制研究，并推进临床评估，以拓展其在糖 尿病相关肾病领域的临床应用。 公告称，此次合作将加快本集团核心项目的临床进展，拓展研发布局，进一步丰富产品管线，为公司在代谢疾病治疗领域的持续创新与长期发展提供有力支 撑。(格隆汇) ...

Core Insights - Junsheng Tai Pharmaceutical-B (02511) announced a collaboration with the Institute of Medicinal Biotechnology of the Chinese Academy of Medical Sciences to evaluate the treatment potential of its core product HTD1801 for chronic kidney disease associated with type 2 diabetes (CKD with T2DM) [1] - The project has received approval from the Chinese Academy of Medical Sciences, focusing on innovative drug mechanisms and clinical research for diabetes and chronic kidney disease [1] - This collaboration aims to leverage the resources of the Institute and the company's expertise in metabolic diseases to accelerate clinical development and enhance product application value [1] Product Development - HTD1801 is the core product of Junsheng Tai Pharmaceutical and the main focus of this collaboration, acting as an oral anti-inflammatory and metabolic regulator targeting the gut-liver system [2] - It features a unique dual mechanism that activates AMPK and inhibits the NLRP3 inflammasome, demonstrating potential in improving multiple health indicators such as blood sugar, blood lipids, kidney function, weight, liver function, and cardiovascular health [2] - Over ten global clinical trials have shown HTD1801's potential for treating comorbidities associated with type 2 diabetes, chronic kidney disease, obesity, dyslipidemia, and fatty liver [2]

Core Insights - The collaboration between Junsheng Tai Pharmaceutical and the Chinese Academy of Medical Sciences aims to evaluate the therapeutic potential of the core product HTD1801 for treating chronic kidney disease associated with type 2 diabetes [1][2] - The project has received approval from the Chinese Academy of Medical Sciences, focusing on innovative drug mechanisms and clinical research for diabetes and chronic kidney disease [1] - The partnership leverages the research advantages of the Academy and the company's expertise in metabolic diseases to accelerate clinical progress and enhance product value [1] Product Details - HTD1801 is the core product of Junsheng Tai Pharmaceutical, designed as an oral anti-inflammatory and metabolic regulator targeting the gut-liver system [2] - It features a unique dual mechanism that activates AMPK and inhibits the NLRP3 inflammasome, showcasing its potential in treating multiple comorbidities such as type 2 diabetes, chronic kidney disease, obesity, dyslipidemia, and fatty liver [2] - Over a dozen global clinical trials have demonstrated that HTD1801 can simultaneously improve various health indicators, including blood sugar, blood lipids, kidney function, weight, liver function, and cardiovascular health [2]